T

Traphaco JSC
VN:TRA

Watchlist Manager
Traphaco JSC
VN:TRA
Watchlist
Price: 72 500 VND 0.14% Market Closed
Market Cap: 3T VND
Section:
 

Relative Value

The Relative Value of one TRA stock under the Base Case scenario is hidden VND. Compared to the current market price of 72 500 VND, Traphaco JSC is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TRA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.2
P/S
P/S
Price to Sales
1.2
vs History
74
vs Industry
64
Median 3Y
1.4
Median 5Y
1.4
Industry
2.7
More Details
13.4
P/E
P/E
Price to Earnings
13.4
vs History
71
vs Industry
31
Median 3Y
15.4
Median 5Y
14.7
Industry
21.4
More Details
10.4
P/OCF
P/OCF
Price to OCF
10.4
vs History
63
vs Industry
33
Median 3Y
16.7
Median 5Y
11.9
Industry
16.8
More Details
13
P/FCFE
P/FCFE
Price to FCFE
13
vs History
52
vs Industry
15
Median 3Y
18.3
Median 5Y
13.5
Industry
23.1
More Details
2
P/B
P/B
Price to Book Value
2
vs History
88
vs Industry
37
Median 3Y
2.3
Median 5Y
2.4
Industry
2.3
More Details
1
EV/S
EV/S
Enterprise Value to Sales
1
vs History
74
vs Industry
70
Median 3Y
1.2
Median 5Y
1.2
Industry
2.9
More Details
1.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.8
vs History
77
vs Industry
71
Median 3Y
2.2
Median 5Y
2.2
Industry
5.5
More Details
5.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
5.8
vs History
77
vs Industry
43
Median 3Y
6.9
Median 5Y
6.5
Industry
13.3
More Details
7.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7.5
vs History
73
vs Industry
41
Median 3Y
8.9
Median 5Y
8.2
Industry
16.5
More Details
8.6
EV/OCF
EV/OCF
Enterprise Value to OCF
8.6
vs History
63
vs Industry
40
Median 3Y
14.1
Median 5Y
10.1
Industry
16
More Details
12.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
12.1
vs History
57
vs Industry
29
Median 3Y
29.6
Median 5Y
14
Industry
18.9
More Details
1.8
EV/IC
EV/IC
Enterprise Value to IC
1.8
vs History
88
vs Industry
36
Median 3Y
2.2
Median 5Y
2.3
Industry
2
More Details

Multiples Across Competitors

TRA Competitors Multiples
Traphaco JSC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Traphaco JSC
VN:TRA
3T VND 1.2 13.4 5.8 7.5
US
Eli Lilly and Co
NYSE:LLY
982.2B USD 16.5 53.3 35.8 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
526.1B USD 5.7 20.9 17.2 22.3
CH
Roche Holding AG
SIX:ROG
277.8B CHF 4.5 29.3 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP 5 31.1 108.8 159.3
CH
Novartis AG
SIX:NOVN
221.8B CHF 4.9 19 12.1 15.6
US
Merck & Co Inc
NYSE:MRK
270.7B USD 4.2 14.2 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.4 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
VN
T
Traphaco JSC
VN:TRA
Average P/E: 23.6
13.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.1
37%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
VN
T
Traphaco JSC
VN:TRA
Average EV/EBITDA: 400.6
5.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.2
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
VN
T
Traphaco JSC
VN:TRA
Average EV/EBIT: 1 713.1
7.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.3
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5

See Also

Summary
TRA intrinsic value, competitors valuation, and company profile.
DCF Valuation
TRA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TRA stock valuation using valuation multiples.
Wall Street Estimates
TRA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TRA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 310,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.